Method for constructing bionic three-dimensional vessel network of human parenchymal viscera

Abstract

The invention relates to a method for constructing a bionic three-dimensional vessel network of human parenchymal viscera, which is characterized by comprising the following steps: acquiring a vessel network image of the liver, heart or kidney of a normal human, and converting a three-dimensional vessel model into a two-dimensional vessel tomograph; placing P(CL-EC) in the middle of fibrin glue and pressing the P(CL-EC) into a diaphragm; punching the degradable diaphragm with a computer laser high-precision perforating machine; co-culturing the degradable diaphragm and bone marrow mesenchymal stem cells of a wild C57BL / 6J mouse, wherein the degradable diaphragm with the middle serial number is co-cultured with the bone marrow mesenchymal stem cells of an SDF-1 / VEGF transfected wild C57BL / 6J mouse; after the cells covers the diaphragm substantially, stacking materials according to the serial numbers, and injecting endothelial progenitor cells of the EGFP gene transfected C57BL / 6J mouse into a preformed hole of a vessel. The method has the advantage of capability of bionically constructing the vessel network of each human parenchymal viscus without the limitation of size.

Description

technical field [0001] The invention relates to a method for constructing a bionic three-dimensional blood vessel network of a human body substantial organ, and belongs to the technical field of bionic organ production. Background technique [0002] Now every year due to mechanical trauma, aging and various diseases, a large number of patients need tissue and organ transplantation. Taking my country as an example, about 1.5 million people need organ transplants every year due to end-stage organ failure, but the number of organs that can be used each year is less than 10,000, and the supply-demand ratio reaches 1:150. Therefore, it is very urgent to use different approaches and methods to solve the serious shortage of organs for transplantation. [0003] Currently commonly used clinical organ transplant donors and their disadvantages: ① The main problem of xenogeneic tissue and organ transplantation is the poor compatibility between the graft and the recipient. ② The main p...

AI Technical Summary

Problems solved by technology

[0003] Currently commonly used clinical organ transplant donors and their disadvantages: ①Xenogeneic tissue and organ transplantation, the main problem is poor compatibility between the graft and the recipient

② Allogeneic tissue and organ transplantation, the main problem is immune rejection and limited donors

③Autologous tissue and organ transplantation, the main problem is the limited number of donors and dysfunction

⑤ Tissue-engineered organs have good histocompatibility, can be produced in large quantities, and do not require immunosuppressive therapy; the main problem is that the technology for constructing tissue-engineered organs is still immature, and there is still a certain distance from large-scale clinical application

However, there are many disadvantages in this vascular network construction method: (1) surgery is required to achieve implantation in the body; (2) the cycle is long; (3) the thickness of the stent system should not be too large; (4) the blood flow in the vascular network is small, which cannot meet Tissue engineered heart, kidney, liver requirements

In addition, the vascular network constructed above is a regular vascular network rather than a bionic vascular network. Compared with a bionic vascular network, a regular vascular network will generate more micro-turbulence when blood cells flow in its lumen, which will increase the probability of thrombus formation.